FCHS First Choice Healthcare Solutions, Inc.
Services-Medical Laboratories · OTC · SEC CIK 1416876 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-552.3%
TTM EPS YoY-518.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-729.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets657.7%
Debt / equity—
Current ratio0.01x
Interest coverage-0.14x
Cash quality & payout
Operating cash flow / net income0.12x
Accruals ratio-645.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20172017-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| Gross profit | $7,350 | — | $29,985 | $1.07M | — |
| SG&A expense | $1.88M | $906,815 | $2.19M | $3.62M | $5.59M |
| Operating income | -$2.67M | -$1.29M | -$2.41M | -$7.02M | -$4.41M |
| Interest expense | $4.71M | $3.35M | $5.92M | $3.71M | — |
| Pretax income | -$6.96M | -$3.74M | -$8.17M | -$9.94M | -$4.39M |
| Income tax | — | $111,950 | — | — | — |
| Net income | -$6.96M | -$3.85M | -$8.17M | -$9.94M | $3.89M |
| EBITDA | -$2.65M | -$1.25M | -$2.37M | -$6.93M | -$3.47M |
| EPS (basic) | — | -0.12 | -0.25 | -0.30 | -0.15 |
| EPS (diluted) | -0.21 | -0.12 | -0.25 | -0.30 | -0.15 |
| Weighted avg. shares (diluted) | 32.96M | 32.96M | 32.96M | 32.96M | 26.66M |
| Banking | |||||
| Deposits | — | — | — | — | $2,269 |
| Balance sheet | |||||
| Cash & equivalents | $5,896 | $19,915 | $12,607 | $7,219 | $2.02M |
| Receivables | $717 | $72,270 | $92,444 | $304,873 | $8.70M |
| Current assets | $6,613 | $92,185 | $107,634 | $1.33M | $12.55M |
| PP&E, net | $146,961 | $222,816 | $262,243 | $470,703 | $2.30M |
| Goodwill | — | — | — | — | $899,465 |
| Total assets | $4.05M | $4.51M | $3.12M | $6.52M | $18.75M |
| Current liabilities | $40.67M | $33.27M | $27.93M | $21.58M | $3.47M |
| Long-term debt | — | — | — | — | $2.69M |
| Total debt | — | — | — | — | $2.69M |
| Total liabilities | $43.58M | $36.98M | $31.65M | $26.92M | $7.27M |
| Shareholders' equity | -$39.53M | -$32.47M | -$28.53M | -$20.41M | $10.97M |
| Net debt | — | — | — | — | $676,110 |
| Shares outstanding | 32.96M | 32.96M | 32.96M | 32.96M | 27.17M |
| Cash flow statement | |||||
| Operating cash flow | -$549,019 | -$1.71M | -$6.80M | -$3.38M | -$1.55M |
| Capital expenditure | — | — | $82,918 | $80,680 | $330,439 |
| Free cash flow | — | — | -$6.88M | -$3.46M | -$1.89M |
| Investing cash flow | $10,000 | $7,000 | $63,779 | -$80,680 | -$330,439 |
| Financing cash flow | $525,000 | $1.71M | $6.74M | $3.46M | -$693,050 |
| Depreciation & amortization | $17,527 | $34,569 | $44,805 | $88,562 | $941,836 |
| Stock-based compensation | — | — | — | $4,188 | $1.17M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.